Advances in the JAK2/STAT3 signaling pathway and its inhibitors in diffuse large B cell lymphoma
- VernacularTitle:JAK2/STAT3信号通路及其抑制剂在弥漫大B细胞淋巴瘤中的研究进展
- Author:
Chuanyang LU
1
;
Qiuni CHEN
1
;
Yuye SHI
1
;
Yuan DENG
1
;
Tingting JI
1
;
Zhengyuan LIU
1
;
Chunling WANG
1
;
Liang YU
2
Author Information
1. Dept. of Hematology，the Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University，Jiangsu Huai’an 223300，China;Key Laboratory of Hematology，Nanjing Medical University，Nanjing 210029，China
2. Dept. of Hematology，the Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University，Jiangsu Huai’an 223300，China
- Publication Type:Journal Article
- Keywords:
Janus kinase;
signal transducer and activator of transcription;
diffuse large B-cell lymphoma;
ruxolitinib
- From:
China Pharmacy
2026;37(5):682-688
- CountryChina
- Language:Chinese
-
Abstract:
Abnormal activation of the Janus kinase/signal transducer and activator of transcription （JAK/STAT） signaling pathway is involved in the pathogenesis of diffuse large B-cell lymphoma （DLBCL）. In recent years， inhibitors targeting JAK2 and STAT3 have emerged as promising therapeutic candidates in DLBCL. This review summarizes the efficacy and safety profiles of JAK2 inhibitors （e.g.， ruxolitinib） and STAT3 inhibitors （direct small-molecule inhibitors， the antisense oligonucleotide， and proteolysis targeting chimeras， etc.） in preclinical models and clinical trials. Accumulating evidence indicates that JAK2 and STAT3 inhibitors exhibit antitumor activity and are generally well tolerated in a subset of DLBCL patients. Meanwhile， the development of novel drug delivery systems has significantly enhanced the stability， bioavailability， and targeting ability of the compounds. Furthermore， JAK2 and STAT3 inhibitors may exhibit synergistic effects when combined with other therapy strategies （such as combinations with B-cell receptor signaling pathway inhibitors， immunomodulators， or other targeted drugs）. However， current clinical applications are still in their early stages. Future research should concentrate on precision treatment strategies based on the genetic subtyping of DLBCL， and further refine the delivery systems for inhibitors as well as combination drug regimens to improve clinical outcomes.
